Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review

This review aimed to investigate the metabolic alterations associated with psychopharmacological treatment of neuropsychiatric disorders, which can significantly impact patients’ physical health and overall quality of life. The study utilized the PRISMA methodology and included cross-sectional, retr...

Full description

Autores:: Sepúlveda-Lizcano, Lizeth
Arenas-Villamizar, Vivian Vanessa
Jaimes Duarte, Enna Beatriz
Garcia-Pacheco, Henry
Silva Paredes, Carlos
Bermudez, Valmore
Rivera-Porras, Diego

Tipo de recurso:

Fecha de publicación:: 2023

Institución:: Universidad Simón Bolívar

Repositorio:: Repositorio Digital USB

Idioma:: eng

id	USIMONBOL2_6c1a766acf2f2c979c8af46a8a9d78ef
oai_identifier_str	oai:bonga.unisimon.edu.co:20.500.12442/16100
network_acronym_str	USIMONBOL2
network_name_str	Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv	Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review
title	Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review
spellingShingle	Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review Metabolism Psychopharmacological treatment Antidepressants Anticonvulsants Antipsychotics
title_short	Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review
title_full	Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review
title_fullStr	Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review
title_full_unstemmed	Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review
title_sort	Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review
dc.creator.fl_str_mv	Sepúlveda-Lizcano, Lizeth Arenas-Villamizar, Vivian Vanessa Jaimes Duarte, Enna Beatriz Garcia-Pacheco, Henry Silva Paredes, Carlos Bermudez, Valmore Rivera-Porras, Diego
dc.contributor.author.none.fl_str_mv	Sepúlveda-Lizcano, Lizeth Arenas-Villamizar, Vivian Vanessa Jaimes Duarte, Enna Beatriz Garcia-Pacheco, Henry Silva Paredes, Carlos Bermudez, Valmore Rivera-Porras, Diego
dc.subject.keywords.eng.fl_str_mv	Metabolism Psychopharmacological treatment Antidepressants Anticonvulsants Antipsychotics
topic	Metabolism Psychopharmacological treatment Antidepressants Anticonvulsants Antipsychotics
description	This review aimed to investigate the metabolic alterations associated with psychopharmacological treatment of neuropsychiatric disorders, which can significantly impact patients’ physical health and overall quality of life. The study utilized the PRISMA methodology and included cross-sectional, retrospective studies, and randomized clinical trials from reputable databases like SCOPUS, CLARIVATE, SCIENCE DIRECT, and PUBMED. Out of the 64 selected studies, various psychotropic drug classes were analyzed, including antidepressants, anticonvulsants, and antipsychotics. Among the antidepressants, such as amitriptyline, Imipramine, and clomipramine, weight gain, constipation, and cardiovascular effects were the most commonly reported metabolic adverse effects. SSRI antidepressants like Fluoxetine, Sertraline, Citalopram, Escitalopram, and Paroxetine exhibited a high prevalence of gastrointestinal and cardiac alterations. Regarding anticonvulsants, valproic acid and Fosphenytoin were associated with adverse reactions such as weight gain and disturbances in appetite and sleep patterns. As for antipsychotics, drugs like Clozapine, Olanzapine, and Risperidone were linked to weight gain, diabetes, and deterioration of the lipid profile. The findings of this review emphasize the importance of continuous monitoring for adverse effects, particularly considering that the metabolic changes caused by psychopharmacological medications may vary depending on the age of the patients. Future research should focus on conducting field studies to further expand knowledge on the metabolic effects of other commonly prescribed psychotropic drugs. Overall, the study highlights the significance of understanding and managing metabolic alterations induced by psychopharmacological treatment to enhance patient care and well-being.
publishDate	2023
dc.date.issued.none.fl_str_mv	2023
dc.date.accessioned.none.fl_str_mv	2025-01-16T17:04:55Z
dc.date.available.none.fl_str_mv	2025-01-16T17:04:55Z
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/article
dc.type.spa.none.fl_str_mv	Artículo científico
dc.identifier.citation.eng.fl_str_mv	Sepúlveda-Lizcano, L., Arenas-Villamizar, V. V., Jaimes-Duarte, E. B., García-Pacheco, H., Paredes, C. S., Bermúdez, V., & Rivera-Porras, D. (2023). Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review. European Journal of Investigation in Health, Psychology and Education, 13(8), 1505-1520. https://doi.org/10.3390/ejihpe13080110
dc.identifier.issn.none.fl_str_mv	22549625 (Electrónico)
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/20.500.12442/16100
dc.identifier.doi.none.fl_str_mv	https://doi.org/10.3390/ejihpe13080110
identifier_str_mv	Sepúlveda-Lizcano, L., Arenas-Villamizar, V. V., Jaimes-Duarte, E. B., García-Pacheco, H., Paredes, C. S., Bermúdez, V., & Rivera-Porras, D. (2023). Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review. European Journal of Investigation in Health, Psychology and Education, 13(8), 1505-1520. https://doi.org/10.3390/ejihpe13080110 22549625 (Electrónico)
url	https://hdl.handle.net/20.500.12442/16100 https://doi.org/10.3390/ejihpe13080110
dc.language.iso.none.fl_str_mv	eng
language	eng
dc.rights.eng.fl_str_mv	Attribution-NonCommercial-NoDerivs 3.0 United States
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.none.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.rights.accessrights.none.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivs 3.0 United States http://creativecommons.org/licenses/by-nc-nd/3.0/us/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.none.fl_str_mv	pdf
dc.publisher.eng.fl_str_mv	MDPI
institution	Universidad Simón Bolívar
bitstream.url.fl_str_mv	https://bonga.unisimon.edu.co/bitstreams/e7f2948e-d03b-4e1b-a54e-9f1f2cf78868/download https://bonga.unisimon.edu.co/bitstreams/477234fc-266a-4e7e-8710-0a31c7b93fc7/download https://bonga.unisimon.edu.co/bitstreams/1e5bb051-d8da-4952-b3c3-9a4f6cf0a9ef/download https://bonga.unisimon.edu.co/bitstreams/75fccf23-b274-486c-9f84-d6f6b29c5bc1/download https://bonga.unisimon.edu.co/bitstreams/7e4a23dd-cf5b-4b48-8c4d-123c413bf055/download
bitstream.checksum.fl_str_mv	733bec43a0bf5ade4d97db708e29b185 50db6991a02d3d52b3deb15b9c169602 2f656a26de8af8c32aaacd5e2a33538c 1d6a2aa037cc556f9bf37889295b1a79 6b1b47c34f5831c1838294cab33c2e1d
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv	repositorio.digital@unisimon.edu.co
_version_	1834107481950781440
spelling	Sepúlveda-Lizcano, Lizethaa9b38b6-2192-45ee-8f83-ec996085429e-1Arenas-Villamizar, Vivian Vanessaac2e1d60-ebd6-4e6b-902d-1ccc0ae16a3c600Jaimes Duarte, Enna Beatriz8b63db5e-5c99-4a31-886c-88b997e9ebe0600Garcia-Pacheco, Henrye4f1a108-a7ba-416f-9dac-e17b2fd7160d600Silva Paredes, Carlos30b53fad-42be-494a-aaf2-6ad5944e23e1-1Bermudez, Valmore820702ba-9b51-41c6-a584-fb7acb935196600Rivera-Porras, Diegoee283aaf-e891-4c69-ae05-7f0998b683b86002025-01-16T17:04:55Z2025-01-16T17:04:55Z2023Sepúlveda-Lizcano, L., Arenas-Villamizar, V. V., Jaimes-Duarte, E. B., García-Pacheco, H., Paredes, C. S., Bermúdez, V., & Rivera-Porras, D. (2023). Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review. European Journal of Investigation in Health, Psychology and Education, 13(8), 1505-1520. https://doi.org/10.3390/ejihpe1308011022549625 (Electrónico)https://hdl.handle.net/20.500.12442/16100https://doi.org/10.3390/ejihpe13080110This review aimed to investigate the metabolic alterations associated with psychopharmacological treatment of neuropsychiatric disorders, which can significantly impact patients’ physical health and overall quality of life. The study utilized the PRISMA methodology and included cross-sectional, retrospective studies, and randomized clinical trials from reputable databases like SCOPUS, CLARIVATE, SCIENCE DIRECT, and PUBMED. Out of the 64 selected studies, various psychotropic drug classes were analyzed, including antidepressants, anticonvulsants, and antipsychotics. Among the antidepressants, such as amitriptyline, Imipramine, and clomipramine, weight gain, constipation, and cardiovascular effects were the most commonly reported metabolic adverse effects. SSRI antidepressants like Fluoxetine, Sertraline, Citalopram, Escitalopram, and Paroxetine exhibited a high prevalence of gastrointestinal and cardiac alterations. Regarding anticonvulsants, valproic acid and Fosphenytoin were associated with adverse reactions such as weight gain and disturbances in appetite and sleep patterns. As for antipsychotics, drugs like Clozapine, Olanzapine, and Risperidone were linked to weight gain, diabetes, and deterioration of the lipid profile. The findings of this review emphasize the importance of continuous monitoring for adverse effects, particularly considering that the metabolic changes caused by psychopharmacological medications may vary depending on the age of the patients. Future research should focus on conducting field studies to further expand knowledge on the metabolic effects of other commonly prescribed psychotropic drugs. Overall, the study highlights the significance of understanding and managing metabolic alterations induced by psychopharmacological treatment to enhance patient care and well-being.pdfengMDPIAttribution-NonCommercial-NoDerivs 3.0 United Stateshttp://creativecommons.org/licenses/by-nc-nd/3.0/us/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Reviewinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1MetabolismPsychopharmacological treatmentAntidepressantsAnticonvulsantsAntipsychoticsRojas, E.; Castro, A.; Manzano, A.; Suárez, M.K.; Lameda, V.; Carrasquero, R.; Nava, M.; Bermúdez, V. Diagnostic Criteria and Management of Metabolic Syndrome: Evolution Overtime. Gac. Medica Caracas 2021, 128, 480–504.Moreira, F.P.; Jansen, K.; Cardoso, T.D.A.; Mondin, T.C.; Magalhães, P.V.; Kapczinski, F.; Souza, L.D.M.; da Silva, R.A.; Oses, J.P.; Wiener, C.D. Metabolic Syndrome and Psychiatric Disorders: A Population-Based Study. Rev. Bras. Psiquiatr. 2019, 41, 38–43.Tubbs, A.S.; Khader, W.; Fernandez, F.; Grandner, M.A. The Common Denominators of Sleep, Obesity, and Psychopathology. Curr. Opin. Psychol. 2020, 34, 84–88.Sugai, T.; Suzuki, Y.; Yamazaki, M.; Shimoda, K.; Mori, T.; Ozeki, Y.; Matsuda, H.; Sugawara, N.; Yasui-Furukori, N.; Minami, Y.; et al. High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey. PLoS ONE 2016, 11, e0166429.Zimmet, P.; Alberti, K.G.M.M.; Shaw, J. Global and Societal Implications of the Diabetes Epidemic. Nature 2001, 414, 782–787.Domecq, J.P.; Prutsky, G.; Leppin, A.; Sonbol, M.B.; Altayar, O.; Undavalli, C.; Wang, Z.; Elraiyah, T.; Brito, J.P.; Mauck, K.F.; et al. Drugs Commonly Associated with Weight Change: A Systematic Review and Meta-Analysis. J. Clin. Endocrinol. Metab. 2015, 100, 363–370.Wang, H.H.; Lee, D.K.; Liu, M.; Portincasa, P.; Wang, D.Q.H. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. Pediatr. Gastroenterol. Hepatol. Nutr. 2015, 23, 189.Núñez-Cortés, J.M.; Mantilla Morató, T.; Toro, R.; Millán Pérez, J.; Mangas Rojas, A.; Ascaso, J.; Civeira, F.; Mostaza, J.M.; Pintó, X.; Valdivielso, P. Metabolic Syndrome in Patients with Clinical Phenotype “Hypertriglyceridemic Waist”. Nutr. Hosp. 2015, 241, e172.Abosi, O.; Lopes, S.; Schmitz, S.; Fiedorowicz, J.G. Cardiometabolic Effects of Psychotropic Medications. Horm. Mol. Biol. Clin. Investig. Gruyter 2018, 36.Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ 2021, 372, n71.Rakitin, A.; Eglit, T.; Kõks, S.; Lember, M.; Haldre, S. Comparison of the Metabolic Syndrome Risk in Valproate-Treated Patients with Epilepsy and the General Population in Estonia. PLoS ONE 2014, 9, e103856.Delacrétaz, A.; Glatard, A.; Dubath, C.; Gholam, M.; Gamma, F.; von Gunten, A.; Conus, P.; Eap, C.B. Valproate Is Associated with Early Decrease of High-Density Lipoprotein Cholesterol Levels in the Psychiatric Population. Basic. Clin. Pharmacol. Toxicol. 2021, 129, 26–35.Gomis, R. Presentation: The Threat of Metabolic Change. Span. J. Cardiol. 2008, 8 (Suppl. SC), 1.Steffens, D.C.; Wei, J.; Krishnan, K.R.R.; Karoly, E.D.; Mitchell, M.W.; O’Connor, C.M.; Kaddurah-Daouk, R. Metabolomic Differences in Heart Failure Patients with and without Major Depression. J. Geriatr. Psychiatry Neurol. 2010, 23, 138–146.Rajjo, T.; Mohammed, K.; Alsawas, M.; Ahmed, A.T.; Farah, W.; Asi, N.; Almasri, J.; Prokop, L.J.; Murad, M.H. Treatment of Pediatric Obesity: An Umbrella Systematic Review. J. Clin. Endocrinol. Metab. 2017, 102, 763–775.de San, H.; de Bogotá, J.; Septiembre, D.C.; Jerónimo, C.; Sánchez, V.; Pablo, J.; Chacón, M.; Tovar Cortés, H.; De, H.; José, S.; et al. Prevalence of metabolic syndrome in patients attending the internal medicine outpatient clinic. Rev. Repert. Med. Y Cirugía 2011, 20, 93–102.Alalwan, A.A.; Friedman, J.; Alfayez, O.; Hartzema, A. Drug Absorption in Bariatric Surgery Patients: A Narrative Review. Health Sci. Rep. 2022, 5, e605.Hinnouho, G.M.; Singh-Manoux, A.; Gueguen, A.; Matta, J.; Lemogne, C.; Goldberg, M.; Zins, M.; Czernichow, S. Metabolically Healthy Obesity and Depressive Symptoms: 16-Year Follow-up of the Gazel Cohort Study. PLoS ONE 2017, 12, e0174678.Piña, I.L.; di Palo, K.E.; Ventura, H.O. Psychopharmacology and Cardiovascular Disease. J. Am. Coll. Cardiol. 2018, 71, 2346–2359.Chen, J.; Yang, Y.; Yu, N.; Sun, W.; Yang, Y.; Zhao, M. Relationship between Gut Microbiome Characteristics and the Effect of Nutritional Therapy on Glycemic Control in Pregnant Women with Gestational Diabetes Mellitus. PLoS ONE 2022, 17, e0267045.Laaboub, N.; Dubath, C.; Ranjbar, S.; Sibailly, G.; Grosu, C.; Piras, M.; Délessert, D.; Richard-Lepouriel, H.; Ansermot, N.; Crettol, S.; et al. Insomnia Disorders Are Associated with Increased Cardiometabolic Disturbances and Death Risks from Cardiovascular Diseases in Psychiatric Patients Treated with Weight-Gain-Inducing Psychotropic Drugs: Results from a Swiss Cohort. BMC Psychiatry 2022, 22, 342.Wolff, J.; Reißner, P.; Hefner, G.; Normann, C.; Kaier, K.; Binder, H.; Hiemke, C.; Toto, S.; Domschke, K.; Marschollek, M.; et al. Pharmacotherapy, Drug-Drug Interactions and Potentially Inappropriate Medication in Depressive Disorders. PLoS ONE 2021, 16, e0255192.Ulrich, S.; Ricken, R.; Adli, M. Tranylcypromine in Mind (Part I): Review of Pharmacology. Eur. Neuropsychopharmacol. 2017, 27, 697–713.Párraga Martínez, I.; López-Torres Hidalgo, J.; Del Campo, J.M.; Villena Ferrer, A.; Morena Rayo, S.; Escobar Rabadán, F. Monitoring Adherence to Antidepressant Treatment in Patients Initiating Antidepressant Treatment. Aten. Primaria 2014, 46, 357–366.Morriss, R.; Tyrer, F.; Zaccardi, F.; Khunti, K. Safety of Anti-depressants in a Primary Care Cohort of Adults with Obesity and Depression. PLoS ONE 2021, 16, e0245722.Pagán-Busigó, J.E.; López-Carrasquillo, J.; Appleyard, C.B.; Torres-Reverón, A. Beyond Depression and Anxiety; a Systematic Review about the Role of Corticotropin-Releasing Hormone Antagonists in Diseases of the Pelvic and Abdominal Organs. PLoS ONE 2022, 17, e0264909.Criado, K.K.; Sharp, W.G.; McCracken, C.E.; de Vinck-Baroody, O.; Dong, L.; Aman, M.G.; McDougle, C.J.; McCracken, J.T.; Eugene Arnold, L.; Weitzman, C.; et al. Overweight and Obese Status in Children with Autism Spectrum Disorder and Disruptive Behavior. Autism 2018, 22, 450–459.Khuda, I.E.; Nazish, S.; Zeeshan, M.A.; Shariff, E.; Aljaafari, D.; Alabdali, M. It Is Illegal to Post This Copyrighted PDF on Any Website. Non-HDL Cholesterol, Obesity, and Metabolic Syndrome in Epileptic Patients. Prim. Care Companion J. Clin. Psychiatry 2022, 24, e1–e6.Dalvi-Garcia, F.; Fonseca, L.L.; Vasoncelos, A.T.R.; Pereira, C.H.; Voit, E.O. A Model of Dopamine and Serotonin-Kynurenine Metabolism in Cortisolemia: Implications for Depression. PLoS Comput. Biol. 2021, 17, e1008956.Correll, C.U.; Agid, O.; Crespo-Facorro, B.; de Bartolomeis, A.; Fagiolini, A.; Seppälä, N.; Howes, O.D. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs 2022, 36, 659–679.Suetani, R.J.; Siskind, D.; Reichhold, H.; Kisely, S. Genetic Variants Impacting Metabolic Outcomes among People on Clozapine: A Systematic Review and Meta-Analysis. Psychopharmacology 2017, 234, 2989–3008.Simon, M.S.; Barton, B.B.; Glocker, C.; Musil, R. A Comprehensive Approach to Predicting Weight Gain and Therapy Response in Psychopharmacologically Treated Major Depressed Patients: A Cohort Study Protocol. PLoS ONE 2022, 17, e0271793.Vasudev, K.; Choi, Y.H.; Norman, R.; Kim, R.B.; Schwarz, U.I. Genetic Determinants of Clozapine-Induced Metabolic Side Effects. Can. J. Psychiatry 2017, 62, 138–149.Siskind, D.J.; Leung, J.; Russell, A.W.; Wysoczanski, D.; Kisely, S. Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. PLoS ONE 2016, 11, e0156208.Ciencia, C.; Médico, E. Weight Gain and Metabolic Change with Predictors of Symptom Improvement in Patients with First Episode Schizophrenia Spectrum Disorder Treated for 12 Months. Schizophr. Res. 2019, 206, 171–176.Liu, Y.K.; Ling, S.; Lui, L.M.W.; Ceban, F.; Vinberg, M.; Kessing, L.V.; Ho, R.C.; Rhee, T.G.; Gill, H.; Cao, B.; et al. Prevalence of Type 2 Diabetes Mellitus, Impaired Fasting Glucose, General Obesity, and Abdominal Obesity in Patients with Bipolar Disorder: A Systematic Review and Meta-Analysis. J. Affect. Disord. 2022, 300, 449–461.Iqbal, E.; Govind, R.; Romero, A.; Dzahini, O.; Broadbent, M.; Stewart, R.; Smith, T.; Kim, C.H.; Werbeloff, N.; MacCabe, J.H.; et al. The Side Effect Profile of Clozapine in Real World Data of Three Large Mental Health Hospitals. PLoS ONE 2020, 15, e0243437.Steuer, A.E.; Schmidhauser, C.; Tingelhoff, E.H.; Schmid, Y.; Rickli, A.; Kraemer, T.; Liechti, M.E. Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans. PLoS ONE 2016, 11, e0150955.Vázquez-Bourgon, J.; Gómez-Revuelta, M.; Mayoral-van Son, J.; Labad, J.; Ortiz-García de la Foz, V.; Setién-Suero, E.; Ayesa-Arriola, R.; Tordesillas-Gutiérrez, D.; Juncal-Ruiz, M.; Crespo-Facorro, B. Pattern of Long-Term Weight and Metabolic Changes after a First Episode of Psychosis: Results from a 10-Year Prospective Follow-up of the PAFIP Program for Early Intervention in Psychosis Cohort. Eur. Psychiatry 2022, 65, E48.Pinzón, J.B.; Serrano, N.C.; Díaz, L.A. Impact of the new definitions in the prevalence of the metabolic syndrome in an adult population at Bucaramanga, Colombia. Biomedica 2007, 27, 172–179.Vázquez-Bourgon, J.; Ibáñez Alario, M.; Mayoral-van Son, J.; Gómez Revuelta, M.; Ayesa Arriola, R.; Juncal Ruiz, M.; Ortiz-García de la Foz, V.; Crespo Facorro, B. A 3-Year Prospective Study on the Metabolic Effect of Aripiprazole, Quetiapine and Ziprasidone: A Pragmatic Clinical Trial in First Episode Psychosis Patients. Eur. Neuropsychopharmacol. 2020, 39, 46–55.Gómez-Revuelta, M.; Pelayo-Terán, J.M.; Juncal-Ruiz, M.; Ortiz-García de la Foz, V.; Vázquez-Bourgon, J.; González-Pinto, A.; Crespo-Facorro, B. Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. Int. J. Neuropsychopharmacol. 2018, 21, 1090–1101.Kahl, K.; Lampen-Inkamp, S.; Claassen, B.; Peschel, T.; Schik, G. E.05.02 Metabolic Alterations and Their Background in Patients with Affective Disorders. Eur. Neuropsychopharmacol. 2010, 20, S211.Fernández-Aranda, F.; Sauchelli, S.; Pastor, A.; Gonzalez, M.L.; de La Torre, R.; Granero, R.; Jiménez-Murcia, S.; Baños, R.; Botella, C.; Fernández-Real, J.M.; et al. Moderate-Vigorous Physical Activity across Body Mass Index in Females: Moderating Effect of Endocannabinoids and Temperament. PLoS ONE 2014, 9, e104534.Castillo Hernández, J.L.; Cuevas González, M.J.; Galiana, M.A.; Romero Hernández, E. Metabolic syndrome, a public health problem with different definitions and criteria. Rev. Médica Univ. Veracruzana 2017, 17, 7–14.Garmendia Lorena, F. Metabolic Syndrome, Artifice or Reality? Ann. Fac. Med. 2020, 81, 92–98.Tabatabaei-Malazy, O.; Moghaddam, S.S.; Rezaei, N.; Sheidaei, A.; Hajipour, M.J.; Mahmoudi, N.; Mahmoudi, Z.; Dilmaghani-Marand, A.; Rezaee, K.; Sabooni, M.; et al. A Nationwide Study of Metabolic Syndrome Prevalence in Iran; A Comparative Analysis of Six Definitions. PLoS ONE 2021, 16, e0241926.Asbjornsdottir, B.; Lauth, B.; Fasano, A.; Thorsdottir, I.; Karlsdottir, I.; Gudmundsson, L.S.; Gottfredsson, M.; Smarason, O.; Sigurdardottir, S.; Halldorsson, T.I.; et al. Meals, Microbiota and Mental Health in Children and Adolescents (MMM-Study): A Protocol for an Observational Longitudinal Case-Control Study. PLoS ONE 2022, 17, e0273855.Voith, V.L. Recent Advances in Psychopharmacology. Tijdschr. Diergeneeskd. 1993, 118 (Suppl. S1), 59S–61S.Maremmani, A.G.I.; Gazzarrini, D.; Fiorin, A.; Cingano, V.; Bellio, G.; Perugi, G.; Maremmani, I. Psychopathology of Addiction: Can the SCL90-Based Five-Dimensional Structure Differentiate Heroin Use Disorder from a Non-Substance-Related Addictive Disorder Such as Gambling Disorder? Ann. Gen. Psychiatry 2018, 17, 3.Guerdjikova, A.I.; McElroy, S.L.; Kotwal, R.; Stanford, K.; Keck, P.E. Psychiatric and Metabolic Characteristics of Childhood versus Adult-Onset Obesity in Patients Seeking Weight Management. Eat. Behav. 2007, 8, 266–276.Lee, K.; Abraham, S.; Cleaver, R. A Systematic Review of Licensed Weight-Loss Medications in Treating Antipsychotic-Induced Weight Gain and Obesity in Schizophrenia and Psychosis. Gen. Hosp. Psychiatry 2022, 78, 58–67.Hod, R.; Mohd Nor, N.H.; Maniam, S. Systematic Review on E-Cigarette and Its Effects on Weight Gain and Adipocytes. PLoS ONE 2022, 17, e0270818.Khalil, H.; Ellwood, L.; Lord, H.; Fernandez, R. Pharmacological Treatment for Obesity in Adults: An Umbrella Review. Ann. Pharmacother. 2020, 54, 691–705.Orzelska-Górka, J.; Mikulska, J.; Wiszniewska, A.; Biała, G. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. Int. J. Mol. Sci. 2022, 23, 10624.Vogel Martinez, M.I.; León, F.; Torres, R.; Crossley, N.A. First and Second Generation Anti-psychotics in Schizophrenia: Efficacy, Effectiveness and Dose Effect. ARS MEDICA J. Med. Sci. 2017, 42.Pañero Herranz, C.; Madrid, A.M. Psychological Aspects, Treatment and Prevention; Universidad Pontificia Comillas: Madrid, Spain, 2021.Pscheidt, S.L.; Zardeto, H.N.; de Sá Junior, A.R.; Schneider, I.J.C. Cardiovascular Diseases and Use of Antipsychotics in Schizophrenia: A Review. J. Bras. Psiquiatr. 2022, 71, 253–272.Panizzutti, B.; Bortolasci, C.C.; Spolding, B.; Kidnapillai, S.; Connor, T.; Richardson, M.F.; Truong, T.T.T.; Liu, Z.S.J.; Gray, L.; Kim, J.H.; et al. Biological Mechanism(S) Underpinning the Association between Antipsychotic Drugs and Weight Gain. J. Clin. Med. 2021, 10, 4095.Liu, H.C.; Yang, S.Y.; Liao, Y.T.; Chen, C.C.; Kuo, C.J. Anti-psychotic Medications and Risk of Acute Coronary Syndrome in Schizophrenia: A Nested Case-Control Study. PLoS ONE 2016, 11, e0163533.Kranzler, H.N.; Cohen, S.D. Psychopharmacologic Treatment of Psychosis in Children and Adolescents. Efficacy and Management. Child Adolesc. Psychiatr. Clin. N. Am. 2013, 22, 727–744.Himmerich, H.; Bentley, J.; Lichtblau, N.; Brennan, C.; Au, K. Facets of Shared Decision-Making on Drug Treatment for Adults with an Eating Disorder. Int. Rev. Psychiatry 2019, 31, 332–346.Singh, R.; Stogios, N.; Smith, E.; Lee, J.; Maksyutynsk, K.; Au, E.; Wright, D.C.; De Palma, G.; Graff-Guerrero, A.; Gerretsen, P.; et al. Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: A scoping review. Ther. Adv. Psychopharmacol. 2022, 20451253221096525.Allison, D.B.; Mentore, J.L.E.; Heo, M.; Chandler, L.P.; Cappelleri, J.C.; Infante, M.C.; Weiden, P.J. Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis. Am. J. Psychiatry 1999, 156, 1686–1696.Palacio-Ortiz, J.D.; Londoño-Herrera, J.P.; Nanclares-Márquez, A.; Robledo-Rengifo, P.; Quintero-Cadavid, C.P. Psychiatric Disorders in Children and Adolescents during the COVID-19 Pandemic. Rev. Colomb. Psiquiatr. 2020, 49, 279–288Stancil, S.L.; Abdel-Rahman, S.; Wagner, J. Developmental Considerations for the Use of Naltrexone in Children and Adolescents. J. Pediatr. Pharmacol. Ther. 2021, 26, 675–695.van Mil, E.G.A.H.; Westerterp, K.R.; Kester, A.D.M.; Delemarre-van De Waal, H.A.; Gerver, W.J.M.; Saris, W.H.M. The Effect of Sibutramine on Energy Expenditure and Body Composition in Obese Adolescents. J. Clin. Endocrinol. Metab. 2007, 92, 1409–1414.Ford, T.C.; Nibbs, R.; Crewther, D.P. Glutamate/GABA+ Ratio Is Associated with the Psychosocial Domain of Autistic and Schizotypal Traits. PLoS ONE 2017, 12, e0181961.Taylor, J.; Stubbs, B.; Hewitt, C.; Ajjan, R.A.; Alderson, S.L.; Gilbody, S.; Holt, R.I.G.; Hosali, P.; Hughes, T.; Kayalackakom, T.; et al. The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis. PLoS ONE 2017, 12, e0168549.Frayne, J.; Watson, S.; Snellen, M.; Nguyen, T.; Galbally, M. The Association between Mental Illness, Psychotropic Medication Use and Hypertensive Disorders in Pregnancy: A Multicentre Study. Pregnancy Hypertens. 2021, 24, 22–26.Ozdemir, A.C.; Wynn, G.M.; Vester, A.; Weitzmann, M.N.; Neigh, G.N.; Srinivasan, S.; Rudd, M.K. GNB3 Overexpression Causes Obesity and Metabolic Syndrome. PLoS ONE 2017, 12, e0188763.Ahrens, K.R.; DuBois, D.L.; Richardson, L.P.; Fan, M.Y.; Lozano, P. Youth in Foster Care with Adult Mentors during Adolescence Have Improved Adult Outcomes. Pediatrics 2008, 121, e246–e252.Planansky, K. Changes in Weight in Patients Receiving a “Tranquilizing” Drug. Psychiatr. Q. 1958, 32, 289–303.Mejaddam, A.; Krantz, E.; Höskuldsdóttir, G.; Fändriks, L.; Mossberg, K.; Eliasson, B.; Trimpou, P.; Landin-Wilhelmsen, K. Comorbidity and Quality of Life in Obesity–a Comparative Study with the General Population in Gothenburg, Sweden. PLoS ONE 2022, 17, e0273553.Oughli, H.; Lenze, E.J.; Locke, A.E.; Yingling, M.D.; Zhong, Y.; Miller, J.P.; Reynolds, C.F.; Mulsant, B.H.; Newcomer, J.W.; Peterson, T.R.; et al. Getting to Precision Psychopharmacology: Combining Clinical and Genetic Information to Predict Fat Gain from Aripiprazole. J. Psychiatr. Res. 2019, 114, 67–74.Schulz, P. Opportunities and Challenges in Psychopharmacology. Dialogues Clin. Neurosci. 2019, 21, 119–130.Goetz, R.L.; Miller, B.J. Meta-Analysis of Ghrelin Alterations in Schizophrenia: Effects of Olanzapine. Schizophr. Res. 2019, 206, 21–26.LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/e7f2948e-d03b-4e1b-a54e-9f1f2cf78868/download733bec43a0bf5ade4d97db708e29b185MD51ORIGINALPDF.pdfPDF.pdfapplication/pdf429029https://bonga.unisimon.edu.co/bitstreams/477234fc-266a-4e7e-8710-0a31c7b93fc7/download50db6991a02d3d52b3deb15b9c169602MD52CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8905https://bonga.unisimon.edu.co/bitstreams/1e5bb051-d8da-4952-b3c3-9a4f6cf0a9ef/download2f656a26de8af8c32aaacd5e2a33538cMD53TEXTPDF.pdf.txtPDF.pdf.txtExtracted texttext/plain71299https://bonga.unisimon.edu.co/bitstreams/75fccf23-b274-486c-9f84-d6f6b29c5bc1/download1d6a2aa037cc556f9bf37889295b1a79MD54THUMBNAILPDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5695https://bonga.unisimon.edu.co/bitstreams/7e4a23dd-cf5b-4b48-8c4d-123c413bf055/download6b1b47c34f5831c1838294cab33c2e1dMD5520.500.12442/16100oai:bonga.unisimon.edu.co:20.500.12442/161002025-01-17 03:04:40.756http://creativecommons.org/licenses/by-nc-nd/3.0/us/Attribution-NonCommercial-NoDerivs 3.0 United Statesopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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

Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review

Publicaciones similares